LDLR Variant (Pro699Leu)

Some people are born with a single letter change in the gene that builds their LDL receptor, the protein the liver uses to clear cholesterol from the blood. When that receptor does not work well, LDL cholesterol stays high for life and the risk of early heart disease climbs sharply, often regardless of how clean someone eats.

The Pro699Leu change is one of thousands of LDLR variants that have been catalogued, but it has not yet been studied in enough detail to know with certainty whether it impairs the receptor or behaves like a harmless typo. Knowing your status, alongside your LDL cholesterol and ApoB (apolipoprotein B, a protein on every harmful cholesterol particle), helps you and a clinician decide how aggressively to treat.

What the LDL Receptor Actually Does

The LDLR gene codes for a protein that sits on the surface of liver cells and grabs LDL particles out of the blood. Once captured, the LDL is pulled inside and broken down, and the receptor recycles back to the surface to do it again. Mutations can disrupt any step in that cycle, including how the receptor is built, how it travels through the cell, how tightly it grips LDL, how it gets pulled inside, or how it returns to the surface.

Liver cells produce most of the LDL receptors in the body, which is why LDLR changes show up so clearly in blood cholesterol numbers. A receptor that fails to clear LDL leaves more cholesterol circulating, and that excess cholesterol is what gets deposited in artery walls over decades.

Why This Specific Variant Sits in a Gray Zone

Across published databases, 2,104 unique LDLR, APOB, and PCSK9 variants have been linked to familial hypercholesterolemia (a condition where high cholesterol is inherited rather than earned through diet). Of those, only 166 had complete, high-quality lab studies showing exactly how they affected the receptor. Roughly 705 variants were classified as pathogenic and 392 as likely pathogenic, but 986 remained variants of uncertain significance, meaning the evidence was not strong enough to call them either way.

Pro699Leu is a missense change, meaning it swaps one amino acid (proline) for another (leucine) at position 699 of the receptor protein. The available research does not characterize this specific change with functional studies or population data, so its pathogenicity has not been firmly established. About 85% of all reported familial hypercholesterolemia variants lack complete functional evidence, and Pro699Leu currently sits in that large group.

How LDLR Variants Affect Heart Disease Risk

When an LDLR variant is shown to disrupt the receptor, the consequences are well documented. People who carry pathogenic LDLR variants have lifelong high LDL cholesterol and a markedly elevated risk of early heart attack, coronary disease, and aortic valve narrowing. In a Dutch cascade screening study of more than 35,000 people, carriers of severe receptor-deficient variants had about 7 times the coronary artery disease risk of non-carriers, while carriers of milder defective variants had roughly 4 times the risk.

The reverse also holds: large genetic studies show that people who inherit LDLR changes that lower LDL cholesterol have proportionally lower coronary heart disease risk over their lifetimes, with the benefit tracking the absolute drop in ApoB. Rare LDLR variants have also been linked to higher risk of aortic stenosis (a stiffening of the valve between the heart and the body's main artery).

What a Single Letter Result Cannot Tell You

A genetic test reports whether you carry the Pro699Leu change, not how much LDL cholesterol you have or how much heart disease risk you face. Because this specific variant has not been functionally characterized, a positive result on its own should not be read as a familial hypercholesterolemia diagnosis. It should prompt a more complete workup including LDL-C, ApoB, and Lp(a) (lipoprotein(a), an inherited cholesterol particle that adds independent risk).

The clearest signal of LDL receptor dysfunction is your actual LDL cholesterol level. In one Austrian screening study, an off-treatment LDL cholesterol of 190 mg/dL or higher caught about 85 out of 100 people with a true familial hypercholesterolemia variant, while clinical scoring systems caught only 54 out of 100. If your LDL-C has been very high since young adulthood, that pattern carries more weight than any single variant call.

How LDLR Variants Are Classified

Genetics labs use the American College of Medical Genetics framework, which combines functional studies, population frequency, family co-segregation, and computer modeling to assign one of five classes. The same variant can land in different classes at different labs based on which evidence each lab counts most heavily. Classification is also revised over time as new data come in.

Functional banding by lab activity is one increasingly used approach: variants with less than 70% of normal receptor activity tend to be called pathogenic, and those above 90% tend to be called benign. Variants in the middle, or those without functional testing at all, often stay labeled uncertain.

Source: Chora et al., Genetics in Medicine 2017; Huijgen et al., European Heart Journal 2012.

Reconciling a Genetic Result with Normal Cholesterol

Some people carry an uncertain LDLR variant but have normal LDL cholesterol, which can feel contradictory. The framework that resolves this is straightforward: the test reports your DNA, not your phenotype. A variant of uncertain significance has not been proven to impair the receptor, and your normal LDL cholesterol is itself evidence pointing toward a benign or weakly active variant. Conversely, very high LDL cholesterol despite a benign variant call still carries the same heart disease risk it would in anyone else. The number that drives outcomes is the cholesterol in your blood, and the gene result is most useful as context for that number.

Reference Ranges Are Not the Right Frame Here

A genetic variant is either present or absent in your DNA. There is no concentration to measure and no normal range in the usual sense. What labs and researchers report instead is a classification (pathogenic, likely pathogenic, uncertain, likely benign, or benign) and, where available, the residual receptor activity associated with that variant. The clinical numbers that matter for risk are downstream: LDL cholesterol, ApoB, and Lp(a).

Because Pro699Leu has not been functionally characterized, it does not yet have an assigned activity percentage or a confirmed pathogenicity class in major databases. Your lab report may list it as a variant of uncertain significance until further evidence accumulates.

Why a Single Reading Is Enough, but Tracking Cholesterol Is Not

Your DNA does not change, so this test only needs to be done once with a high-quality lab. What does need ongoing tracking is the cholesterol biology downstream of the receptor. Get a baseline LDL cholesterol and ApoB, retest in 3 to 6 months if you change your diet or start a medication, and at least once a year thereafter to confirm the trajectory. Over time, the trend in your ApoB and LDL-C tells you far more about your actual heart disease risk than any single variant call.

Variant classifications can also be updated. If your result is currently uncertain, it is reasonable to ask the lab once every few years whether new evidence has shifted the call.

What to Do If You Carry the Variant

A positive result, especially when paired with high LDL cholesterol or a family history of early heart attack or stroke, is worth investigating with a lipidologist or preventive cardiologist. The decision pathway typically includes confirming your LDL-C and ApoB on more than one occasion, ordering Lp(a) at least once, and screening first-degree relatives so they can be tested too. Cascade testing in families with confirmed pathogenic variants is one of the highest-yield uses of genetic information in cardiovascular medicine.

If your variant is uncertain but your LDL cholesterol is consistently high (above 190 mg/dL untreated), most lipid specialists treat the lipid pattern aggressively regardless of the genetic call. The genetic result adds information, but the cholesterol number is what drives the treatment decision.

When Results Can Be Misleading

• Lab-to-lab classification differences: the same variant can be called pathogenic at one lab and uncertain at another, depending on which evidence each lab weighs most heavily. If your result is borderline, ask whether a second lab would interpret it differently.
• Outdated classifications: variant calls are revised as new functional and population data emerge. A result from several years ago may no longer reflect current consensus.
• Confusing the variant with the diagnosis: carrying an LDLR variant is not the same as having familial hypercholesterolemia. The diagnosis is based on lifelong high LDL cholesterol, family history, and physical signs, with the genetic result as one supporting piece.
• Reading too much into an uncertain call: an uncertain variant is exactly that. It should prompt closer monitoring of cholesterol numbers, not panic or lifelong assumptions about disease.